Chardan Capital Maintains Buy on Homology Medicines, Lowers Price Target to $8
Chardan Capital analyst Matthew Barcus maintains Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $10 to $8.
Homology Medicines Q3 EPS $(0.59) Down From $(0.54) YoY, Sales $802.00K Down From $1.68M YoY
Homology Medicines (NASDAQ:FIXX) reported quarterly losses of $(0.59) per share. This is a 9.26 percent decrease over losses of $(0.54) per share from the same period last year. The company reported $802.00 thousand in
Baird Maintains Outperform on Homology Medicines, Lowers Price Target to $9
Baird analyst Madhu Kumar maintains Homology Medicines (NASDAQ:FIXX) with a Outperform and lowers the price target from $10 to $9.
Chardan Capital Maintains Buy on Homology Medicines, Lowers Price Target to $10
Chardan Capital analyst Matthew Barcus maintains Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $14 to $10.
BTIG Maintains Buy on Homology Medicines, Lowers Price Target to $12
BTIG analyst Robert Hazlett maintains Homology Medicines (NASDAQ: FIXX) with a Buy and lowers the price target from $29 to $12.BTIG analyst Robert Hazlett maintains Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $29 to $
Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder
Homology Medicines Inc (NASDAQ: FIXX) announced the details of HMI-204, its optimized, in vivo, one-time gene therapy candidate for metachromatic leukodystrophy (MLD).
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers
Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results.
Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380.
79 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.